NTRK1 and cancer: First, the clinical efficacy of inhibiting a ligand-receptor interaction with antibodies has been clearly demonstrated in the Receptor Tyrosine Kinase (RTK) pathway field with clinically validated antibodies inhibiting HER2, EGFR, VEGFR, PDGFR and FGFR signaling in numerous cancers [94,98].